Tamoxifen and endometrial cancer: Most cancers are early stage and highly curable Journal Article
| Author: | Barakat, R. |
| Article Title: | Tamoxifen and endometrial cancer: Most cancers are early stage and highly curable |
| Abstract: | A large randomised trial comparing tamoxifen with placebo for breast cancer treatment has demonstrated an average annual hazard rate for endometrial cancer in the placebo group of 0.2/1000 compared to 1.6/1000 for the tamoxifen-treated group, with tamoxifen causing a 7.5-fold increase in the relative risk of endometrial cancer. If the effect of tamoxifen on the endometrium is that of a weak oestrogen agonist, one could expect associated endometrial cancers to have clinical characteristics comparable to those associated with unopposed oestrogen i.e. low stage, well differentiated turnouts that are highly curable. |
| Keywords: | controlled study; clinical trial; cancer risk; conference paper; endometrium cancer; controlled clinical trial; breast cancer; randomized controlled trial; tamoxifen; human; female; priority journal |
| Journal Title: | European Journal of Cancer |
| Volume: | 34 |
| Issue: | Suppl. 4 |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 1998-08-01 |
| Start Page: | S49 |
| End Page: | S50 |
| Language: | English |
| PROVIDER: | scopus |
| DOI: | 10.1016/S0959-8049(98)00112-9 |
| DOI/URL: | |
| Notes: | Conference Paper -- Export Date: 12 December 2016 -- Source: Scopus |
